Exploring Cutting-Edge Advances in Future Testing for Multiple Sclerosis

Blood Tests May Predict Progression of Primary Progressive Multiple Sclerosis

Introduction

Recent advancements suggest that doctors might soon utilize blood tests to forecast the progression of primary progressive multiple sclerosis (PPMS) in patients. This innovation could pave the way for earlier interventions and customized treatment plans, ultimately helping to decelerate the disease’s advancement.

Understanding Primary Progressive Multiple Sclerosis

Primary progressive multiple sclerosis is a distinct form of multiple sclerosis (MS) characterized by a gradual worsening of symptoms from the onset of the disease. Unlike other MS types, which feature periods of relapse and remission, PPMS presents a continuous decline in function.

Research Background

Researchers have made strides in identifying biomarkers that can predict the course of multiple sclerosis, yet there remains a need for more refined indicators specifically for the progressive variant. Dr. Manuel Comabella and a global team from the Multiple Sclerosis Center of Catalonia (Cemcat) are addressing this gap. Their findings, published in the Journal of Neurology, Neurosurgery and Psychiatry, reveal that certain MS-related markers in the blood can forecast how disability in PPMS patients will evolve over time.

Key Findings on Biomarkers

The study identified that measuring the levels of NfL (neurofilament light chain), GFAP (glial fibrillary acidic protein), and CHI3L1 (chitinase 3-like 1) in the blood could effectively predict changes in disability among patients with primary progressive multiple sclerosis. Notably, higher protein levels correlated with increased disability scores, with this correlation consistent over periods of six and ten years following the initial assessment.

The Decade-Long Investigation

In this comprehensive study, researchers tracked 141 patients with primary progressive multiple sclerosis from 18 different European MS centers over a decade. The goal was to determine if the three biomarkers could predict the rate of disability progression. Patients were categorized into inflammatory and non-inflammatory groups based on specific criteria, such as recent relapses or active lesions visible on MRI.

Methodology

Researchers evaluated the patients’ blood markers and disability levels at the study’s onset and again after intervals of two, six, and nearly ten years. The Expanded Disability Status Scale (EDSS), a standard assessment tool for MS, was employed to measure disability, which encompasses various functional impairments, from mobility to cognitive issues.

Link Between Biomarkers and Disability Progression

At the beginning of the study, biomarker levels were assessed as “average,” with participants averaging an EDSS score of 4, indicating significant disability but the ability to walk without assistance for about 500 meters. While these biomarkers provided some insight into patient condition, they did not fully capture the severity of MS at any given time.

Significant Correlations Found

Encouragingly, after two years, researchers identified that a doubling of initial biomarker levels related to increases in EDSS scores. Specifically, each doubling in biomarker levels corresponded to a roughly 0.1-point increase in the disability score. Such changes, even small, can significantly affect daily living, such as the ability to walk independently.

Longitudinal Analysis

The correlation between biomarker levels and disability progression remained consistent at both the six-year and ten-year follow-ups. Notably, among the non-inflammatory patient group, increases in CHI3L1 levels were consistently associated with worsened disability over time.

Future Implications

This groundbreaking study indicates that biomarkers currently useful for other MS forms may also be applicable in diagnosing and monitoring primary progressive multiple sclerosis. Given that traditional assessment methods like MRI and spinal taps can be complex and invasive, blood tests measuring these biomarkers present a simpler, cost-effective, and less invasive alternative for monitoring disease progression.

Next Steps in Research

Further testing and clinical trials are necessary to advance this concept and develop blood tests as a reliable diagnostic tool for primary progressive multiple sclerosis.

References

1. Fissolo N, Benkert P, Sastre-Garriga J, et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. Published online November 8, 2023. doi:https://doi.org/10.1136/jnnp-2023-332251.
2. “How Is Multiple Sclerosis Diagnosed?” National Multiple Sclerosis Society, www.nationalmssociety.org/Symptoms-Diagnosis/Diagnosing-MS. Accessed 17 Apr. 2024.
3. “Primary Progressive Multiple Sclerosis (PPMS).” National Multiple Sclerosis Society, www.nationalmssociety.org/What-is-MS/Types-of-MS/Primary-progressive-MS#section-2. Accessed 22 Apr. 2024.
4. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2019;90(8):870-881. doi:https://doi.org/10.1136/jnnp-2018-320106.
5. Yang Z, Wang KKW. Glial Fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends in Neurosciences. 2015;38(6):364-374. doi:https://doi.org/10.1016/j.tins.2015.04.003.
6. Yu JE, Yeo IJ, Han SB, et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Experimental & Molecular Medicine. 2024;56(1):1-18. doi:https://doi.org/10.1038/s12276-023-01131-9.
7. “Expanded Disability Status Scale (EDSS).” Multiple Sclerosis Society UK, www.mssociety.org.uk/about-ms/treatments-and-therapies/getting-treatment-for-ms/expanded-disability-status-scale#:~:text=The%20Expanded%20Disability%20Status%20Scale%20(EDSS)%20is%20a%20way%20of,3.5%2C%204%20and%20so%20on. Accessed 23 Apr. 2024.